These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11590254)

  • 21. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.
    Van Wyck DB
    Nephrol Dial Transplant; 2000; 15 Suppl 3():36-9. PubMed ID: 11032356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Factors affecting the response to erythropoiesis-stimulating agents].
    Jauréguy M; Choukroun G
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S274-82. PubMed ID: 17373270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
    Markham A; Bryson HM
    Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical factors influencing sensitivity and response to epoetin.
    Richardson D
    Nephrol Dial Transplant; 2002; 17 Suppl 1():53-9. PubMed ID: 11812914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel aspects of vitamin C in epoetin response.
    Tarng DC
    J Chin Med Assoc; 2007 Sep; 70(9):357-60. PubMed ID: 17908648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
    Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
    Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of anemia by convective treatments.
    Locatelli F; Manzoni C; Del Vecchio L; Di Filippo S; Pontoriero G; Cavalli A
    Contrib Nephrol; 2011; 168():162-172. PubMed ID: 20938137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
    Sitter T; Bergner A; Schiffl H
    Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
    Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D;
    Lancet; 2007 Oct; 370(9596):1415-21. PubMed ID: 17950856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes.
    Saunders S; MacLeod ML; Salyers V; MacMillan PD; Ogborn MR
    J Clin Nurs; 2013 Aug; 22(15-16):2206-15. PubMed ID: 23336392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
    Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R
    J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher target haemoglobin level and early anaemia treatment: different or complementary concepts?
    Macdougall LC
    Nephrol Dial Transplant; 2000; 15 Suppl 3():3-7. PubMed ID: 11032350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
    Deicher R; Hörl WH
    Drugs; 2004; 64(5):499-509. PubMed ID: 14977387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.